文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

恢复期血浆抗体水平与Covid-19死亡风险

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
PubMed 文献 · N Engl J Med · 2021-01-13
一句话结论住院未机械通气的Covid-19患者,输注高滴度抗SARS-CoV-2 IgG血浆者30天死亡风险低于低滴度者(RR 0.66),已机械通气者无此获益。

该研究为基于美国国家登记处的回顾性研究,纳入3082例住院成人Covid-19患者,检测所用恢复期血浆的抗SARS-CoV-2 IgG抗体水平,主要终点为输注后30天内死亡。高滴度组30天死亡率为22.3%(115/515),中滴度组27.4%(549/2006),低滴度组29.6%(166/561)。抗体水平与死亡风险的关联受机械通气状态影响:输血前未机械通气者高滴度组较低滴度组30天死亡风险更低(RR 0.66,95%CI 0.48-0.91),已机械通气者无效应(RR 1.02,95%CI 0.78-1.32)。

要点

  • 输血前未机械通气的住院Covid-19患者,高滴度抗SARS-CoV-2 IgG血浆较低滴度血浆30天死亡风险更低(RR 0.66,95%CI 0.48-0.91)。
  • 输血前已接受机械通气的患者,高滴度血浆对30天死亡风险无效应(RR 1.02,95%CI 0.78-1.32)。
  • 30天死亡率:高滴度组22.3%(115/515)、中滴度组27.4%(549/2006)、低滴度组29.6%(166/561)。
  • 抗体水平与死亡风险的关联受机械通气状态影响,选择血浆时应考虑患者是否已机械通气。

适用人群与场景

  • 美国国家登记处中住院的成人Covid-19患者,纳入截至2020年7月4日、有血浆抗SARS-CoV-2抗体水平数据和30天死亡率数据的患者。
  • 分析按输血前是否接受机械通气分层。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:基于美国国家登记处的回顾性研究,纳入3082例住院成人Covid-19患者。
  • 主要终点:输注后30天内死亡;高滴度组22.3%(115/515)、中滴度组27.4%(549/2006)、低滴度组29.6%(166/561)。
  • 输血前未机械通气者:高滴度组较低滴度组30天死亡风险更低(RR 0.66,95%CI 0.48-0.91)。
  • 输血前已机械通气者:高滴度组与低滴度组30天死亡风险无差异(RR 1.02,95%CI 0.78-1.32)。

证据类型、等级与局限

  • 证据类型:回顾性研究(基于美国国家登记处)。
  • 局限:回顾性设计,非随机分组,可能存在混杂;抗体水平与死亡风险的关联为观察性关联。

对床旁实践的改变

  • 对住院未机械通气的Covid-19患者,选择恢复期血浆时可考虑使用抗SARS-CoV-2 IgG抗体水平较高的血浆,以降低30天死亡风险。
  • 对已接受机械通气的Covid-19患者,高滴度血浆未显示降低30天死亡风险,不应期望通过选择高滴度血浆改善预后。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be passively transferred to the plasma recipient. Whether convalescent plasma with high antibody levels rather than low antibody levels is associated with a lower risk of death is unknown.

METHODS: In a retrospective study based on a U.S. national registry, we determined the anti-SARS-CoV-2 IgG antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19. The primary outcome was death within 30 days after plasma transfusion. Patients who were enrolled through July 4, 2020, and for whom data on anti-SARS-CoV-2 antibody levels in plasma transfusions and on 30-day mortality were available were included in the analysis.

RESULTS: Of the 3082 patients included in this analysis, death within 30 days after plasma transfusion occurred in 115 of 515 patients (22.3%) in the high-titer group, 549 of 2006 patients (27.4%) in the medium-titer group, and 166 of 561 patients (29.6%) in the low-titer group. The association of anti-SARS-CoV-2 antibody levels with the risk of death from Covid-19 was moderated by mechanical ventilation status. A lower risk of death within 30 days in the high-titer group than in the low-titer group was observed among patients who had not received mechanical ventilation before transfusion (relative risk, 0.66; 95% confidence interval [CI], 0.48 to 0.91), and no effect on the risk of death was observed among patients who had received mechanical ventilation (relative risk, 1.02; 95% CI, 0.78 to 1.32).

CONCLUSIONS: Among patients hospitalized with Covid-19 who were not receiving mechanical ventilation, transfusion of plasma with higher anti-SARS-CoV-2 IgG antibody levels was associated with a lower risk of death than transfusion of plasma with lower antibody levels. (Funded by the Department of Health and Human Services and others; ClinicalTrials.gov number, NCT04338360.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021. PMID: 33523609. doi:10.1056/NEJMoa2031893

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。